(NASDAQ: IPSC) Century Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.
Century Therapeutics's earnings in 2026 is -$109,788,000.On average, 8 Wall Street analysts forecast IPSC's earnings for 2026 to be -$96,784,759, with the lowest IPSC earnings forecast at -$97,599,598, and the highest IPSC earnings forecast at -$96,965,834. On average, 8 Wall Street analysts forecast IPSC's earnings for 2027 to be -$89,016,628, with the lowest IPSC earnings forecast at -$97,599,598, and the highest IPSC earnings forecast at -$77,952,926.
In 2028, IPSC is forecast to generate -$78,496,152 in earnings, with the lowest earnings forecast at -$79,854,217 and the highest earnings forecast at -$76,051,635.